Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics


Arrowhead Pharmaceuticals, Inc. (ARWR): $34.20

0.87 (+2.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARWR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARWR POWR Grades


  • ARWR scores best on the Value dimension, with a Value rank ahead of 66.69% of US stocks.
  • The strongest trend for ARWR is in Quality, which has been heading down over the past 179 days.
  • ARWR ranks lowest in Momentum; there it ranks in the 12th percentile.

ARWR Stock Summary

  • For ARWR, its debt to operating expenses ratio is greater than that reported by merely 12.57% of US equities we're observing.
  • With a price/sales ratio of 34.12, Arrowhead Pharmaceuticals Inc has a higher such ratio than 94.93% of stocks in our set.
  • Revenue growth over the past 12 months for Arrowhead Pharmaceuticals Inc comes in at 80.89%, a number that bests 89.79% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Arrowhead Pharmaceuticals Inc, a group of peers worth examining would be ALLO, CGEM, DNLI, ARVN, and BCAB.
  • ARWR's SEC filings can be seen here. And to visit Arrowhead Pharmaceuticals Inc's official web site, go to arrowheadpharma.com.

ARWR Valuation Summary

  • ARWR's price/earnings ratio is -55.6; this is 252.33% lower than that of the median Healthcare stock.
  • ARWR's price/sales ratio has moved NA NA over the prior 209 months.
  • Over the past 209 months, ARWR's EV/EBIT ratio has gone NA NA.

Below are key valuation metrics over time for ARWR.

Stock Date P/S P/B P/E EV/EBIT
ARWR 2021-08-31 65.0 16.0 -55.6 -51.4
ARWR 2021-08-30 64.7 16.0 -55.3 -51.1
ARWR 2021-08-27 64.0 15.8 -54.7 -50.5
ARWR 2021-08-26 62.1 15.3 -53.1 -49.0
ARWR 2021-08-25 62.1 15.3 -53.1 -49.0
ARWR 2021-08-24 61.0 15.0 -52.1 -48.0

ARWR Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 221.34%.
  • Its 5 year revenue growth rate is now at 54399.15%.
  • Its 2 year net cashflow from operations growth rate is now at 46.17%.
ARWR's revenue has moved up $49,635,454 over the prior 34 months.

The table below shows ARWR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 144.424 148.799 -182.988
2021-09-30 138.287 171.224 -140.848
2021-06-30 107.6379 184.491 -125.9067
2021-03-31 89.12263 180.6738 -109.5939
2020-12-31 79.84049 -110.7831 -102.6115
2020-09-30 87.99207 -95.39157 -84.55323

ARWR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARWR has a Quality Grade of C, ranking ahead of 55.82% of graded US stocks.
  • ARWR's asset turnover comes in at 0.171 -- ranking 211th of 682 Pharmaceutical Products stocks.
  • COLL, CRBP, and VBIV are the stocks whose asset turnover ratios are most correlated with ARWR.

The table below shows ARWR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.171 1 -0.460
2021-03-31 0.153 1 -0.385
2020-12-31 0.149 1 -0.363
2020-09-30 0.158 1 -0.397
2020-06-30 0.241 1 -0.218
2020-03-31 0.303 1 0.013

ARWR Price Target

For more insight on analysts targets of ARWR, see our ARWR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $87.92 Average Broker Recommendation 1.59 (Moderate Buy)

ARWR Stock Price Chart Interactive Chart >

Price chart for ARWR

ARWR Price/Volume Stats

Current price $34.20 52-week high $93.66
Prev. close $33.33 52-week low $27.87
Day low $32.50 Volume 753,700
Day high $34.25 Avg. volume 769,911
50-day MA $41.67 Dividend yield N/A
200-day MA $56.28 Market Cap 3.62B

Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio


Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.


ARWR Latest News Stream


Event/Time News Detail
Loading, please wait...

ARWR Latest Social Stream


Loading social stream, please wait...

View Full ARWR Social Stream

Latest ARWR News From Around the Web

Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Arrowhead finishes enrollment in phase 2b trial of ARO-ANG3 for mixed dyslipidemia

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached full planned enrollment of more than 180 people in the phase 2b trial of ARO-ANG3 to treat patients with mixed dyslipidemia. The study, dubbed ARCHES-2, is expected to be completed around the end 2022 and the company intends to report topline data in H1 2023. Dyslipidemia...

Seeking Alpha | February 24, 2022

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

PASADENA, Calif., February 24, 2022--Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia

Yahoo | February 24, 2022

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

PASADENA, Calif., February 18, 2022--Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases

Yahoo | February 18, 2022

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

PASADENA, Calif., February 17, 2022--Arrowhead presented clinical data on ARO-HIF2 in patients with renal cell carcinoma at 2022 ASCO GU

Yahoo | February 17, 2022

The Best Russell 2000 Stocks to Buy Before they Rebound

Some of the best stocks in the market are among the best Russell 2000 stocks to buy.

Alex Sirois on InvestorPlace | February 15, 2022

Read More 'ARWR' Stories Here

ARWR Price Returns

1-mo -19.17%
3-mo -22.26%
6-mo -51.95%
1-year -52.89%
3-year 36.85%
5-year 2,120.78%
YTD -48.42%
2021 -13.59%
2020 20.97%
2019 410.71%
2018 237.50%
2017 137.42%

Continue Researching ARWR

Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6453 seconds.